Li Siyu, Zhao Wenyang, Wang Dan, Chen Lei, Feng Yigeng, Sun Peng
Surgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai 200032, China.
J Cancer. 2025 Jul 11;16(10):3261-3269. doi: 10.7150/jca.112954. eCollection 2025.
Neuregulin-1 (NRG1) levels were elevated in prostate cancer patients receiving androgen deprivation therapy (ADT). However, it remains unclear whether NRG1 levels could predict castration-resistant prostate cancer (CRPC) progression. Prostate cancer patients were divided into CRPC and NCRPC (non-CRPC) groups. Baseline clinicopathological characteristics and prostate-specific antigen (PSA) levels were compared among two groups. Subsequently, the levels of NRG1 in blood and tumor tissue were detected using enzyme-linked immunosorbent assay, western blotting, and qPCR. The predictive value of NRG1 was evaluated using receiver operating characteristic (ROC) analysis. Meanwhile, the correlation of NRG1 with Gleason score and PSA levels was analyzed using Spearman analysis. The comparison analysis showed that TNM classification, Gleason scores, and PSA levels were significantly correlated to CRPC. Moreover, the serum NRG1 and the protein and mRNA levels of NRG1 were higher in CRPC patients than in NCRPC patients. ROC analysis unveiled that NRG1 levels in the patients before ADT could predict CRPC progression. Moreover, Spearman analysis also showed that NRG1 was correlated to Gleason scores and PSA levels. Serum NRG1, NRG1 protein, and NRG1 mRNA in tumor tissue from prostate cancer patients before ADT could predict the incidence of CRPC in patients receiving ADT.
接受雄激素剥夺治疗（ADT）的前列腺癌患者中神经调节蛋白-1（NRG1）水平升高。然而，NRG1水平是否能够预测去势抵抗性前列腺癌（CRPC）进展仍不清楚。前列腺癌患者被分为CRPC组和NCRPC（非CRPC）组。比较两组的基线临床病理特征和前列腺特异性抗原（PSA）水平。随后，采用酶联免疫吸附测定、蛋白质印迹法和定量聚合酶链反应检测血液和肿瘤组织中NRG1的水平。使用受试者工作特征（ROC）分析评估NRG1的预测价值。同时，采用Spearman分析分析NRG1与Gleason评分和PSA水平的相关性。比较分析表明，TNM分期、Gleason评分和PSA水平与CRPC显著相关。此外，CRPC患者的血清NRG1以及NRG1的蛋白质和mRNA水平高于NCRPC患者。ROC分析表明，ADT前患者的NRG1水平可预测CRPC进展。此外，Spearman分析还表明，NRG1与Gleason评分和PSA水平相关。ADT前前列腺癌患者肿瘤组织中的血清NRG1、NRG1蛋白和NRG1 mRNA可预测接受ADT患者的CRPC发生率。
